BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) EV/Sales
As of 16 October 2026, BeOne Medicines Ltd. - Sponsored ADR (ONC) trades at a EV/Sales of 6.1×. Over the past ten years it has ranged from 4.1× (April 2024) to 673× (September 2017); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.6× | 23.05% |
| FY2024 | 4.5× | (29.42%) |
| FY2023 | 6.4× | (52.95%) |
| FY2022 | 13.7× | (16.04%) |
| FY2021 | 16.3× | (71.15%) |
| FY2020 | 56.5× | 162.30% |
| FY2019 | 21.5× | (30.90%) |
| FY2018 | 31.2× | 110.30% |
| FY2017 | 14.8× | (86.11%) |
| FY2016 | 107× | 492.30% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.6× | (11.26%) |
| Mar 2026 | 5.1× | (8.23%) |
| Dec 2025 | 5.6× | (18.17%) |
| Sep 2025 | 6.8× | 30.22% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| ARGX argenex SE compare | 8.9× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| RVMD Revolution Medicines, Inc. compare | 1,287× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)